URGN Q4 2019 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$40M

Net Income

-$39M

EPS (Diluted)

$-1.84

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$202M

Total Liabilities

$22M

Stockholders' Equity

$180M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$40M	-$24M	-65.9%
Net Income	-$39M	-$24M	-64.3%